Kyverna Therapeutics reported Phase 2 data for KYV‑101, a CD19 CAR‑T regimen, showing clinical responses in a small cohort of generalized myasthenia gravis (gMG) patients. Six treated patients demonstrated substantial improvements on MG‑ADL and QMG scales, with several reaching minimal symptom expression. The single‑dose therapy produced cytokine release syndrome in all patients but mostly Grade 1–2 events. Investigators compared KYV‑101 outcomes favorably to data from Vyvgart, Ultomiris and other emerging cell therapies — while noting cross‑trial limitations and small sample size. If sustained in larger cohorts, an effective CAR‑T for refractory autoimmune disease would reshape treatment paradigms; next steps include phase 3 enrollment and broader safety monitoring for cell‑therapy‑specific toxicities.